The Pulse Check

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

Jan 15, 2026

•

11 min read

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

Jason Segal

The Pulse Check

Jan 14, 2026

•

7 min read

The Art of the Capital Raise

Jason Segal

The Pulse Check

The Problem With Being the Best Stock in the Market

Jan 13, 2026

•

9 min read

The Problem With Being the Best Stock in the Market

Jason Segal

The Pulse Check

What happens when pharma’s biggest accidental blockbuster comes off patent?

Jan 12, 2026

•

9 min read

What happens when pharma’s biggest accidental blockbuster comes off patent?

Jason Segal

The Pulse Check

Biotech’s biggest week starts as the M&A window opens

Jan 9, 2026

•

7 min read

Biotech’s biggest week starts as the M&A window opens

Jason Segal

The Pulse Check

The $12M Prize: How PER Survived Two Board Coups and Lived to Fight On

Jan 8, 2026

•

8 min read

The $12M Prize: How PER Survived Two Board Coups and Lived to Fight On

Jason Segal

The Pulse Check

What does it mean to be a "platform technology"?

Jan 7, 2026

•

5 min read

What does it mean to be a "platform technology"?

Jason Segal

Noxopharm (ASX: NOX)

Selling Too Early: The Trade That Made Nyrada’s Run Possible

Jan 6, 2026

•

9 min read

Selling Too Early: The Trade That Made Nyrada’s Run Possible

Jason Segal

The Pulse Check

Day #1: The Biotech 165 Challenge Begins

Jan 5, 2026

•

13 min read

Day #1: The Biotech 165 Challenge Begins

Jason Segal

The Pulse Check

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Dec 19, 2025

•

11 min read

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Jason Segal

The Pulse Check

Putting ASX Healthcare in the Hot Seat in 2026

Dec 18, 2025

•

6 min read

Putting ASX Healthcare in the Hot Seat in 2026

Jason Segal

The Pulse Check

Same Result. Two Markets. Very Different Answers.

Dec 17, 2025

•

9 min read

Same Result. Two Markets. Very Different Answers.

Jason Segal

The Pulse Check

The Holiday Trade I like to do once a Year

Dec 16, 2025

•

7 min read

The Holiday Trade I like to do once a Year

Jason Segal

The Pulse Check

Trump floats new cannabis rules: Weeding out the good from the bad

Dec 15, 2025

•

11 min read

Trump floats new cannabis rules: Weeding out the good from the bad

Jason Segal

The Pulse Check

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Dec 12, 2025

•

9 min read

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Jason Segal

The Pulse Check

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Dec 11, 2025

•

9 min read

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Jason Segal

Imugene (ASX: IMU)

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Dec 10, 2025

•

9 min read

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Jason Segal

The Pulse Check

Immutep drops a US$370M deal... at 6:54pm

Dec 9, 2025

•

7 min read

Immutep drops a US$370M deal... at 6:54pm

Jason Segal

The Pulse Check

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Dec 8, 2025

•

11 min read

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Jason Segal

The Pulse Check

Are AI-Predicted Clinical Trials the Future of Drug Development?

Dec 5, 2025

•

5 min read

Are AI-Predicted Clinical Trials the Future of Drug Development?

Jason Segal

The Pulse Check

The Moment Invion (IVX) Became “Investible” for me

Dec 4, 2025

•

7 min read

The Moment Invion (IVX) Became “Investible” for me

Jason Segal

The Pulse Check

Dec 3, 2025

•

7 min read

The Hidden Signals Found in AGM Updates

Jason Segal

Visionflex Group (ASX:VFX)

Dec 2, 2025

•

6 min read

Inside the Visionflex Lazarus Story

Jason Segal

The Pulse Check

What happens when a biotech stock goes up on "no news"...

Dec 1, 2025

•

5 min read

What happens when a biotech stock goes up on "no news"...

Jason Segal

The Pulse Check

Biotech green shoots emerge in Australia and the US

Nov 28, 2025

•

4 min read

Biotech green shoots emerge in Australia and the US

Jason Segal

The Pulse Check

The moment that Chinese biotechs went from 'too hard' to 'too hard to ignore'

The Art of the Capital Raise

The Problem With Being the Best Stock in the Market

What happens when pharma’s biggest accidental blockbuster comes off patent?

Biotech’s biggest week starts as the M&A window opens

The $12M Prize: How PER Survived Two Board Coups and Lived to Fight On

What does it mean to be a "platform technology"?

Selling Too Early: The Trade That Made Nyrada’s Run Possible

Day #1: The Biotech 165 Challenge Begins

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Putting ASX Healthcare in the Hot Seat in 2026

Same Result. Two Markets. Very Different Answers.

The Holiday Trade I like to do once a Year

Trump floats new cannabis rules: Weeding out the good from the bad

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Immutep drops a US$370M deal... at 6:54pm

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Are AI-Predicted Clinical Trials the Future of Drug Development?

The Moment Invion (IVX) Became “Investible” for me

The Hidden Signals Found in AGM Updates

Inside the Visionflex Lazarus Story

What happens when a biotech stock goes up on "no news"...

Biotech green shoots emerge in Australia and the US

The Armchair Analyst